 |
Background: Chronic low back pain (CLBP) is one of the leading causes of disability in the world population. In 2017, in central Europe and North America, prevalence of CLBP was 12.51% and 9.80% respectively. The rehabilitation of the abdominal muscles plays an important role in the management of CLBP in physiotherapy, notably the deeper abdominal muscle, namely the transversus abdominis.
Objectives: The main objective of this study is to prove that a biofeedback device of the transversus abdominis, named Blueback Physio®, developed by the Blueback company, improves the management of patients suffering from this pain.
Design: The clinical trial is designed as a prospective, monocentric, comparative, open-label randomized and parallel group study.
Method: 41 subjects were included in this study and divided into two groups, one control group, in which the subjects used the device without visual biofeedback, and one intervention group, where the subjects used the complete biofeedback. The study included patients cared in day or full hospitalization in Clinique FSEF Rennes-Beaulieu as part of the PRESDO program (”programme de prévention secondaire des dorso-lombalgies”).
Results: The probability of the intervention group achieving control of the voluntary contraction of the transversus abdominis earlier than the control group is 79% with a p-value of 0.004. Moreover, the use of Blueback Physio® allows a better control of the voluntary contraction of this muscle. Finally, the clinical protocol improves overall patient well-being.
